{
  "relevance_rule": {},
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "Sessions mentioning any of the following competitor asset names: Adstiladrin (nadofaragene firadenovec), Anktiva (N-803, Nogapendekin alfa inbakicept), Cretostimogene Grenadenorepvec (CG0070), Oncofid-P-B, TLD-1433, Detalimogene Voraplasmid (EG-70), TARA-002, Imfinzi (durvalumab), Tecentriq (atezolizumab), sasanlimab, Keytruda (pembrolizumab), gemcitabine, docetaxel, rescue BCG, UGN-102, UGN-103, Bavencio (avelumab), Padcev (enfortumab vedotin), Trodelvy (sacituzumab govitecan)",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Adstiladrin",
          "nadofaragene firadenovec",
          "Anktiva",
          "N-803",
          "Nogapendekin alfa inbakicept",
          "Cretostimogene Grenadenorepvec",
          "CG0070",
          "Oncofid-P-B",
          "TLD-1433",
          "Detalimogene Voraplasmid",
          "EG-70",
          "TARA-002",
          "Imfinzi",
          "durvalumab",
          "Tecentriq",
          "atezolizumab",
          "sasanlimab",
          "Keytruda",
          "pembrolizumab",
          "gemcitabine",
          "docetaxel",
          "rescue BCG",
          "UGN-102",
          "UGN-103",
          "Bavencio",
          "avelumab",
          "Padcev",
          "enfortumab vedotin",
          "Trodelvy",
          "sacituzumab govitecan"
        ],
        "categories": [],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "This rule is based on explicit competitor asset names, which can be matched using keywords. It is mutually exclusive from other rules as it is specific to asset names."
    },
    {
      "priority": "High",
      "rule_text": "Sessions mentioning any of the following trial names: CORE-001, QUILT3.032, KEYNOTE-676, KEYNOTE-057, BOND-003, ORION-BC, LEGEND, ADVANCED-2, ABLE-22, ALBAN, POTOMAC, CREST, QUILT-2.004, BRIDGE, PATAPSCO, ENVISION, UTOPIA, PIVOT-006, CORE-008, ATLAS, KEYNOTE-992, NIAGARA, VOLGA",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "CORE-001",
          "QUILT3.032",
          "KEYNOTE-676",
          "KEYNOTE-057",
          "BOND-003",
          "ORION-BC",
          "LEGEND",
          "ADVANCED-2",
          "ABLE-22",
          "ALBAN",
          "POTOMAC",
          "CREST",
          "QUILT-2.004",
          "BRIDGE",
          "PATAPSCO",
          "ENVISION",
          "UTOPIA",
          "PIVOT-006",
          "CORE-008",
          "ATLAS",
          "KEYNOTE-992",
          "NIAGARA",
          "VOLGA"
        ],
        "categories": [],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "This rule is based on explicit trial names, which can be matched using keywords. It is mutually exclusive from other rules as it is specific to trial names."
    },
    {
      "priority": "High",
      "rule_text": "Sessions mentioning any of the following patient populations: High risk NMIBC BCG-unresponsive, intermediate risk NMIBC, MIBC",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "High risk NMIBC BCG-unresponsive",
          "intermediate risk NMIBC",
          "MIBC"
        ],
        "categories": [],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "This rule is based on explicit patient population terms, which can be matched using keywords. It is mutually exclusive from other rules as it is specific to patient populations."
    },
    {
      "priority": "High",
      "rule_text": "Sessions mentioning the keyword 'bladder sparing'",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "bladder sparing",
          "bladder-sparing"
        ],
        "categories": [],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "This rule is based on a specific keyword, which can be matched using keywords. It is mutually exclusive from other rules as it is specific to the bladder sparing concept."
    }
  ]
}